Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, et al. Carbapenemase-Producing Organisms: A Global Scourge. Clin Infect Dis. 2018;66(8):1290-1297.

Huang T-, Shen Z-, Sleckman BP, Tyler JK. The histone chaperone ASF1 regulates the activation of ATM and DNA-PKcs in response to DNA double-strand breaks. Cell Cycle. 2018;17(12):1413-1424.

Chen Y-, Chen Z, Du Y-. Immunohistochemical analysis of RHAMM expression in normal and neoplastic human tissues: a cell cycle protein with distinctive expression in mitotic cells and testicular germ cells. Oncotarget. 2018;9(30):20941-20952.

Curtis BR, Hsu Y-, Podoltsev N, Lacy J, Curtis S, Samuel MS, et al. Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Blood. 2018;131(13):1486-1489.

Gold SL, Cohen-Mekelburg S, Rosenblatt R, Jessurun J, Sharaiha R, Halazun K, et al. An Overt, Obscure Gastrointestinal Bleed Caused by a Primary Small Bowel Fibroblastic Reticular Cell Sarcoma. ACG Case Rep J. 2018;5:e22.

Yang RK, Nazeef M, Patel SS, Mattison R, Yang DT, Ranheim EA, et al. Improving bone marrow biopsy quality through peer discussion and data comparisons: A single institution experience. Int J Lab Hematol. 2018;40(4):419-426.

Navrazhina K, Petukhova T, Wildman HF, Magro CM, Minkis K. Endocrine mucin-producing sweat gland carcinoma of the scalp treated with Mohs micrographic surgery. JAAD Case Rep. 2018;4(9):887-889.

Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F, et al. Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Mol Ther Nucleic Acids. 2018;13:334-346.

Chedgy EC, Vandekerkhove G, Herberts C, Annala M, Donoghue AJ, Sigouros M, et al. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. J Pathol. 2018;246(2):244-253.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, Van Besien K, et al. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leuk Lymphoma. 2018;59(1):256-258.